

**INFORMATION DISCLOSURE CITATION**

Docket No.: RLL-293US Serial No.: 10/552,456

Applicants: MEHTA et al.

Filed: 10/7/2005

Group:

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
S1A1	2,490,714	12/6/1949	Searle	260	239	
S1A2	5,001,160	3/19/1991	McPherson et al.	514	255	
S1A3	5,164,402	11/17/1992	Brighty	514	300	
S1A4	5,179,108	1/12/1993	George et al.	514	319	
S1A5	6,313,312	11/6/2001	Banks et al.	548	452	
S1A6	7,288,562	10/30/2007	Mehta et al.	514	412	
S1A7	2003/0105071	6/5/2003	Cuny et al.	514	210.2	
S1A8	2003/0162780	8/28/2003	Brotherton-Pleiss et al.	514	235.5	
S1A9	2003/0171362	9/11/2003	Madera et al.	514	218	
S1A10	2006/0287380	12/21/2006	Salman et al.	514	412	

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO
S1B1	CA 2,155,320	8/19/1993	Canada	C07D	211/68	
S1B2	EP 0 413 455	2/20/1991	EPO	C07D	401/04	
S1B3	EP 0 613 232	8/31/1994	EPO	H02M	3/335	
S1B4	EP 0 863 141	9/9/1998	EPO	C07D	401/06	
S1B5	EP 0 930 298	7/21/1999	EPO	C07D	211/46	
S1B6	WO 98/53814	12/3/1998	PCT	A61K	31/395	
S1B7	WO 99/43657	9/2/1999	PCT	C07D	211/26	
S1B8	WO 01/42212	6/14/2001	PCT	C07D	211/48	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

SUPPLEMENTAL

Docket No.: RLL-293US

Serial No.: 10/552,456

Applicants: MEHTA *et al.*

Filed: 10/7/2005

Group:

S1B9	WO 01/42213	6/14/2001	PCT	C07D	211/58	
S1B10	WO 01/47893	7/5/2001	PCT	C07D	221/24	
S1B11	WO 01/90081	11/29/2001	PCT	C07D	241/08	
S1B12	WO 01/90082	11/29/2001	PCT	C07D	241/08	
S1B13	WO 02/00652	1/3/2002	PCT	C07D	453/02	
S1B14	WO 02/04402	1/17/2002	PCT	C07C	219/10	
S1B15	WO 02/006241	1/24/2002	PCT	C07D	223/16	
S1B16	WO 02/051841	7/4/2002	PCT	C07D	453/02	
S1B17	WO 02/053564	7/11/2002	PCT	C07D	453/02	
S1B18	WO 03/033495	4/24/2003	PCT	C07D	453/02	
S1B19	WO 03/048124	6/12/2003	PCT	C07D	211/26	
S1B20	WO 03/048125	6/12/2003	PCT	C07D	211/58	
S1B21	WO 2004/004629	1/15/2004	PCT	A61K		
S1B22	WO 2004/005252	1/15/2004	PCT	C07D	209/52	
S1B23	WO 2004/014363	2/19/2004	PCT	A61K	31/40	
S1B24	WO 2004/014853	2/19/2004	PCT	C07D	209/02	
S1B25	WO 2004/018422	3/4/2004	PCT	C07D	209/52	
S1B26	WO 2004/052857	6/24/2004	PCT	C07D	209/52	
S1B27	WO 2004/056767	7/8/2004	PCT	C07D	207/14	
S1B28	WO 2004/056810	7/8/2004	PCT	C07D	405/12	
S1B29	WO 2004/056811	7/8/2004	PCT	C07D	405/12	
S1B30	WO 2004/067510	8/12/2004	PCT	C07D	209/52	
S1B31	WO 2004/069835	8/19/2004	PCT	C07D	471/08	
S1B32	WO 2004/089363	10/21/2004	PCT	A61K	31/403	
S1B33	WO 2004/089899	10/21/2004	PCT	C07D	209/52	
S1B34	WO 2004/089900	10/21/2004	PCT	C07D	209/52	
S1B35	WO 2005/092341	10/6/2005	PCT	A61K	31/496	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE CITATION

SUPPLEMENTAL

Docket No.: RLL-293US

Serial No.: 10/552,456

Applicants: MEHTA et al.

Filed: 10/7/2005

Group:

	S1B36	WO 2006/003587	1/12/2006	PCT	A61K	9/16	
	S1B37	WO 2006/035282	4/6/2006	PCT	A61K	31/439	
	S1B38	WO 2006/064304	6/22/2006	PCT	C07D	209/52	

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	s1C1	Brighty et al., "Synthesis of (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-Amino-3-azabicyclo[3.1.0]hexane, a Novel Achiral Diamine", <i>Synlett</i> , 1097-1099 (1996)
	s1C2	Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", <i>Journal of Organic Chemistry</i> , 65:6283-6287 (2000)
	s1C3	Shacklett and Smith, "The Preparation of Substituted Benzilic Acids", <i>Journal of the American Chemical Society</i> , 75:2654-2657 (1953)
	s1C4	Nkpa and Chedekel, "Mechanistic Studies on the Addition of Cysteine to 3,4-Dihydroxyphenylalanine", <i>Journal of Organic Chemistry</i> , 46:213-215 (1981)
	s1C5	Kadin and Cannon, "Esters of N-Methyl-3-hydroxypiperidine Having Psychotomimetic Activity. II", <i>Journal of Organic Chemistry</i> , 27:240-245 (1962)
	s1C6	Weinstock et al., "A General, One-Step Synthesis of $\alpha$ -keto Esters", <i>Synthetic Communications</i> , 11(12):943-946 (1981)
	s1C7	Vogel et al., 1996. <i>Vogel's Textbook of Practical Organic Chemistry</i> . 5th Edition. USA: Prentice Hall, 1046-1047.
	s1C8	Bundgaard, H., 1985. <i>Design of Prodrugs</i> . Elsevier.
	s1C9	Kaiser et al., "Synthesis and Antimuscarinic Activity of Some 1-Cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted piperazinyl)-2-propanones and Related Compounds", <i>Journal of Medicinal Chemistry</i> , 36(5):610-616 (1993)
	s1C10	Carter et al., "Analogues of Oxybutynin. Synthesis and Antimuscarinic and Bladder Activity of Some Substituted 7-Amino-1-hydroxy-5-heptyn-2-ones and Related Compounds", <i>Journal of Medicinal Chemistry</i> , 34(10):3065-3074 (1991)
	s1C11	Wess et al., "Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: A review", <i>Life Sciences</i> , 72:2047-2054 (2003)
	s1C12	O'Neill, "Unusual suspect for antipsychotic-induced diabetes", <i>Drug Discovery Today</i> , 10(20):1338 (2005)
	s1C13	Michel and Hegde, "Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?", <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> , 374:79-85 (2006)

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION		Docket No.: RLL-293US	Serial No.: 10/552,456
SUPPLEMENTAL		Applicants: MEHTA <i>et al.</i>	
		Filed: 10/7/2005	Group:

s1C14	Latifpour <i>et al.</i> , "Effects of Experimental Diabetes on Biochemical and Functional Characteristics of Bladder Muscarinic Receptors", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>248</u> (1):81-88 (1989)
s1C15	Carrier and Aronstam, "Altered Muscarinic Receptor Properties and Function in the Heart in Diabetes", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>242</u> (2):531-535 (1987)
s1C16	Ahrén <i>et al.</i> , "Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse", <i>Diabetologia</i> , <u>39</u> :383-390 (1996)
s1C17	Abrams <i>et al.</i> , "Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder", <i>British Journal of Pharmacology</i> , <u>148</u> (5):565-578 (2006)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	